Frailty is being increasingly studied as a predictor of adverse outcomes.

Cumulative evidence has associated frailty with an increased risk of adverse health-related outcomes including falls, disability, hospitalizations and mortality.

Measuring frailty may represent a comprehensive tool for risk prediction.

FARGO is a multicentre, prospective cohort study of patients 55 years old or older with confirmed or suspected gynecologic cancer, undergoing cytoreductive or high-risk surgery with or without chemotherapy.

The primary objective of FARGO is to evaluate the performance of preoperative frailty assessment based on the Frailty Phenotype (FP), compared to a perioperative cardiovascular risk assessment based on the combination of preoperative Revised Cardiac Risk Index (RCRI), age and occurrence of myocardial injury after noncardiac surgery (MINS), in predicting the composite of all-cause death or new disability at 6 months after surgery.

Download FARGO Overview (PDF)
Study Type


Study Design

Multi-centre, prospective and longitudinal, cohort study

NO. of Countries


NO. of Sites


NO. of Participants


Study Period

2022 - 2024



Hamilton Health Sciences: New Investigator Fund

PHRI: Transforming Tomorrow Today

Hamilton Academic Health Sciences Organization (HAHSO): Innovation Grant

Back To Top